Cagrilintide: research, legal status and who sells it

What it is

Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that promotes satiety [8]. It has been tested on its own and together with semaglutide, a combination known as CagriSema [9].

Research status

In a 26-week phase 2 trial of 706 adults with overweight or obesity, cagrilintide produced 6.0% to 10.8% average weight loss across five doses, compared with 3.0% on placebo; the highest dose also beat the comparator liraglutide (10.8% versus 9.0%) [8]. Nausea was reported by 20% to 47% of people on cagrilintide versus 18% on placebo [8]. In the phase 3 REDEFINE 1 trial, the cagrilintide–semaglutide combination produced 20.4% average weight loss at 68 weeks versus 3.0% on placebo; gastrointestinal adverse events affected about 80% of people on the combination and 40% on placebo [9]. In adults with type 2 diabetes (REDEFINE 2), weight fell 13.7% with the combination versus 3.4% with placebo [10].

Regulatory status

Cagrilintide is not approved in the US, the EU, the UK or Canada [11][3][2][5]. The FDA states that cagrilintide cannot be used in compounding under federal law and is not a component of any FDA-approved drug [1]. It is not named in Australia’s Poisons Standard [6] or on WADA’s 2026 Prohibited List, although WADA’s section S0 bans substances with no current approval for human therapeutic use [7].

Quality and testing considerations

With no approved product anywhere we track, every cagrilintide or “CagriSema” vial sold online is unapproved. The FDA’s general warning applies: unapproved versions of these drugs do not undergo its review for safety, effectiveness or quality [1]. Its warning letters also make clear that a “research use only” label does not change how a product marketed for people is treated [12].

Where it’s sold

No approved cagrilintide product exists; the tables below track unapproved “research” listings and prices.